Lumida
/ALMS
⌘K
Alumis Inc

Alumis Inc

ALMS
$23.03USD-4.72%-1.14 today

MARKET CAP

3.1B

P/E (TTM)

FWD P/E

DAY RANGE

$22 – $24

52W RANGE

$4
$31

AI Summary

Stalk
StalkMedium

ALMS is in a Stage 4 decline with a breakdown under short EMAs and now approaches the rising 200-day SMA. Extreme oversold readings grant mean-reversion permission for a medium-term bullish stance, but price remains extended below key EMAs with no clear reversal. Execution should await a bounce and acceptance at the 200-day SMA. A failure to hold that support would negate the bullish setup.

  • Envudeucitinib ONWARD3 trial: 75% PASI 90 & 54% PASI 100 at 48 weeks
  • $502.3M cash & equivalents support operations into Q4 2027
  • Q2 2026 revenue $1.7M down 37% YoY vs. $3.47M consensus
Full analysis →

Buying

7

institutions

Selling

7

institutions

New Positions

3

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY8.22 M231.26 M+1.05 M+46.4%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUYNEW4.22 M92.94 M+4.22 M+0.0%0.02%
JC

Jpmorgan Chase & Co

Q2 2026

BUY969.62 K26.41 M+108.04 K+51.7%0.00%
MM

Millennium Management LLC

Q2 2026

BUY660.14 K18.58 M+53.86 K+39.1%0.01%
WP

Woodline Partners LP

Q2 2026

BUYNEW486.05 K13.68 M+486.05 K+0.0%0.04%
VI

Voloridge Investment Management, LLC

Q2 2026

SELL320.86 K9.03 M+-428.24 K-45.3%0.04%
AC

Aqr Capital Management LLC

Q2 2026

SELL146.44 K4.12 M+-245.00+27.5%0.00%
MC

Moore Capital Management, LP

Q2 2026

BUY136.80 K3.85 M+95.43 K+322.4%0.06%
CA

Citadel Advisors LLC

Q2 2026

SELL99.70 K2.81 M+-470.01 K-77.7%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL24.40 K686.62 K+-358.19 K-91.8%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL23.34 K656.65 K+-51.83 K-60.4%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL14.81 K416.78 K+-12.77 K-31.4%0.00%
FC

Farallon Capital Management LLC

Q1 2026

BUYNEW11.00 K242.33 K+11.00 K+0.0%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL0.000.00+-256.00-100.0%0.00%